STOCK TITAN

Moderna Stock Price, News & Analysis

MRNA Nasdaq

Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.

Moderna (MRNA) remains at the forefront of mRNA technology innovation, developing transformative therapies for infectious diseases, oncology, and rare conditions. This dedicated news hub provides investors and healthcare professionals with essential updates directly from the company and verified sources.

Access official press releases covering clinical trial results, regulatory milestones, and strategic partnerships, alongside analysis of quarterly earnings and pipeline developments. Our curated collection ensures you stay informed about Moderna's progress in advancing mRNA-based medicines without promotional bias.

Key updates include developments in respiratory vaccines, cancer immunotherapy candidates, and rare disease treatments. Bookmark this page for real-time access to Moderna's verified announcements and objective reporting on one of biotechnology's most innovative platforms.

Rhea-AI Summary

Moderna announces it will take over as the marketing authorization holder for its COVID-19 vaccine, SpikevaxTM, in Japan starting August 1, 2022. This transition from Takeda includes responsibilities for import, local regulations, development, quality assurance, and commercialization. Takeda will continue to provide distribution support during a transitional period. This move aims to strengthen Moderna's commercial organization in Japan as it continues to combat the COVID-19 pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
covid-19
-
Rhea-AI Summary

Moderna (Nasdaq: MRNA) will participate in a fireside chat at the UBS 2022 Global Healthcare Conference on May 24 at 9:15 a.m. ET. A live webcast will be available on the company's investor website, with a replay accessible for 30 days post-event. Moderna, known for its mRNA technology, has evolved from a research company to a leader in developing vaccines and therapeutics across various diseases, including COVID-19, reinforcing its position in the biopharmaceutical sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
conferences
-
Rhea-AI Summary

IAVI and Moderna announced a Phase I clinical trial in Rwanda and South Africa to assess the safety and immunogenicity of an mRNA HIV vaccine antigen (mRNA-1644). This trial, known as IAVI G003, follows promising results from a prior study that indicated 97% of participants developed targeted immune responses. The trial aims to enroll 18 healthy, HIV-negative adults who will receive two doses of the vaccine. This initiative is supported by the U.S. government and the Bill & Melinda Gates Foundation, aiming to strengthen scientific capacity in regions heavily impacted by HIV.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
Rhea-AI Summary

Moderna detailed advancements in its mRNA platform during its 5th Annual Science and Technology Day, focusing on innovative delivery methods, including pulmonary applications. The company is collaborating with Vertex to develop treatments for cystic fibrosis via inhalation. Evidence supports the safety of its COVID-19 vaccines for pregnant and breastfeeding women. The firm emphasizes the importance of mRNA stability for product shelf-life, achieving improved manufacturing processes. Moderna's ongoing research aims to optimize clinical applications of mRNA across various diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.42%
Tags
none
-
Rhea-AI Summary

Moderna, Inc. (NASDAQ:MRNA) announced the immediate departure of its Chief Financial Officer, Jorge Gomez, amidst an ongoing internal investigation at his previous employer, Dentsply Sirona Inc. In light of this, David Meline, the recently retired CFO, will resume his role as CFO while the company searches for a new candidate. Moderna emphasizes that these changes come with risks and uncertainties, and encourages stakeholders to refer to its latest filings for detailed risk factors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.72%
Tags
none
-
Rhea-AI Summary

Moderna (NASDAQ:MRNA) will host its in-person Science and Technology Day for analysts and investors on May 17, 2022, at 9:00 a.m. ET in Boston, MA. Key presentations will be made by President Stephen Hoge, Chief Scientific Officer Melissa Moore, and other scientists highlighting advances in mRNA technology.

A live webcast will be available on Moderna's investor website, with a replay accessible for one year. Moderna has transformed significantly over the past decade, developing a diverse portfolio of vaccines and therapeutics, particularly noted for its effective COVID-19 vaccine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
conferences
Rhea-AI Summary

Moderna reported strong Q1 2022 results, achieving revenues of $6.1 billion and a net income of $3.7 billion, resulting in a diluted EPS of $8.58. The company reaffirmed its 2022 advance purchase agreements totaling $21 billion and outlined plans for four Phase 3 programs in the second quarter, including COVID booster and flu vaccines. Moderna's pipeline now has 46 programs with 29 in clinical trials, showing robust progress in both preventive and therapeutic mRNA applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.81%
Tags
-
Rhea-AI Summary

Moderna (NASDAQ: MRNA) has submitted a variation for conditional marketing authorization to the European Medicines Agency (EMA) for its COVID-19 vaccine, Spikevax, targeting children six months to under six years. This follows the EMA's positive recommendation for use in children aged six years and older. Positive interim results indicated strong antibody responses and a favorable safety profile from the Phase 2/3 KidCOVE study. Efficacy estimates for the younger age group showed 51% effectiveness against Omicron. The company also continues to explore booster doses for pediatric populations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.69%
Tags
covid-19
-
Rhea-AI Summary

Moderna plans to establish a state-of-the-art mRNA vaccine manufacturing facility in Quebec, with an annual production capacity of up to 100 million doses. This facility is part of a ten-year strategic partnership with the Government of Canada aimed at enhancing pandemic preparedness. Following the expected certification by Health Canada, the facility will produce vaccines for respiratory viruses, including COVID-19. Construction is set to begin in 2022, with operations anticipated by 2024, creating hundreds of jobs and bolstering Canada's life sciences ecosystem.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.69%
Tags
partnership
Rhea-AI Summary

Moderna, Inc. (NASDAQ: MRNA) has submitted a request for emergency use authorization (EUA) of its COVID-19 vaccine, mRNA-1273, for children aged 6 months to under 6 years. This submission is based on positive results from the Phase 2/3 KidCOVE study, which showed a robust antibody response and favorable safety profile. Vaccine efficacy was reported at 51% for the 6 months to < 2 years age group and 37% for the 2 years to < 6 years group, similar to adult efficacy. The EUA submission will be finalized next week as Moderna continues to research booster doses for pediatric cohorts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
covid-19

FAQ

What is the current stock price of Moderna (MRNA)?

The current stock price of Moderna (MRNA) is $26.25 as of October 14, 2025.

What is the market cap of Moderna (MRNA)?

The market cap of Moderna (MRNA) is approximately 10.4B.
Moderna

Nasdaq:MRNA

MRNA Rankings

MRNA Stock Data

10.40B
360.89M
7.24%
74.89%
15.38%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE